Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology

Document Type

Article

Publication Date

9-26-2019

Publication Title

J dermatolog treat

Abstract

Background: Successful clinical data on halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis are published. This article charts its formulation development. Methods: Dermal deposition, clinical efficacy and synergistic effect of HP and TAZ delivered by polymeric emulsion technology was compared to HP 0.05% cream (Ultravate) and TAZ 0.1% cream (Tazorac); skin hydration and barrier maintenance with vehicle lotion through Trans Epidermal Water Loss (TEWL) and corneometry using human cadaver tissue; and steroid potency by vasoconstrictor assay (VCA) in healthy volunteers. Safety and tolerability evaluated in clinical studies and patient preference questionnaire. Results: HP/TAZ lotion, using polymeric emulsion technology demonstrated better active ingredient delivery than HP 0.05% or TAZ 0.1% creams; supported by synergistic clinical data, with high HP potency outcome. Efficacy was rapid and sustained posttreatment. Layering TAZ 0.1% cream onto HP 0.05% cream had a negative effect on receptor phase levels. HP/TAZ lotion provided rapid and sustained increases in skin moisturization and gradual decreases in TEWL. Most subjects responded favorably to questions on the physical attributes of the vehicle lotion. Conclusions: Fixed combination HP 0.01%/TAZ 0.045% lotion formulation utilizing innovative polymeric emulsion technology and optimal selection of solvents/emollients/humectants, has recently been developed. Features inherent in the technology translate into rapid, sustained efficacy, low irritation and good patient acceptance.

PubMed ID

31522563

ePublication

ePub ahead of print

First Page

1

Last Page

8

Find It @ Sladen

Share

COinS